Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Sandrine Degryse,C E de Bock,Sofie Demeyer,I Govaerts,Simon Bornschein,Delphine Verbeke,Kris Jacobs,S Binos,David A. Skerrett-Byrne,Heather C. Murray,Nicole M. Verrills,P Van Vlierberghe,Jan Cools,Matthew D. Dun

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

2018

Sandrine Degryse
C E de Bock
Sofie Demeyer
I Govaerts
Simon Bornschein
Delphine Verbeke
Kris Jacobs
S Binos
David A. Skerrett-Byrne
Heather C. Murray
Nicole M. Verrills
P Van Vlierberghe
Jan Cools
Matthew D. Dun

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Keywords:

Genetics
Cancer research
Mutant
Lymphoblastic Leukemia
T cell
Biology
Signal transduction
PI3K/AKT/mTOR pathway
Protein kinase B
Protein kinase A
Kinase
Janus kinase 3
Upstream and downstream (transduction)
Janus kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations